Abiola B. Bolarinwa

Hematology

200 1st St Sw
Rochester, MN 55905

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

ICC/WHO-Defined and NGS-Annotated Idiopathic Hypereosinophilia (iHES/iHE): Mutations, Clinical and Treatment Details, and Predictors of Survival.

ICC/WHO-Defined and NGS-Annotated Idiopathic Hypereosinophilia (iHES/iHE): Mutations, Clinical and Treatment Details, and Predictors of Survival.

Journal: American journal of hematology

Published: June 03, 2026

Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.

Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.

Journal: American journal of hematology

Published: May 13, 2026

Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.

Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.

Journal: American journal of hematology

Published: March 30, 2026

Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma.

Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma.

Journal: Blood advances

Published: March 06, 2026

CSF3R-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patients.

CSF3R-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patients.

Journal: Haematologica

Published: October 11, 2025

Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients.

Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients.

Journal: Blood cancer journal

Published: May 26, 2025

CSF3R mutations and variants in myeloid neoplasms: associated phenotypes, co-mutations, and survival trends.

CSF3R mutations and variants in myeloid neoplasms: associated phenotypes, co-mutations, and survival trends.

Journal: Haematologica

Published: April 10, 2025

Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma.

Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma.

Journal: American journal of hematology

Published: February 10, 2025

Monoclonal Gammopathies in Africa.

Monoclonal Gammopathies in Africa.

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 06, 2025

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes.

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes.

Journal: Blood cancer journal

Published: December 27, 2024

Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma.

Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma.

Journal: Blood cancer journal

Published: November 27, 2024

Antioxidant supplementation for sickle cell disease.

Antioxidant supplementation for sickle cell disease.

Journal: The Cochrane database of systematic reviews

Published: May 22, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026